SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. - ALIM
- NEW YORK , July 26, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Alimera Sciences, Inc. (Nasdaq: ALIM), relating to its proposed merger with ANI Pharmaceuticals, Inc. Under the terms of the agreement, Alimera Sciences shareholders will receive $5.50 per share, and one contingent value right which shall represent the right to receive up to $0.50 per share contingent on reaching certain net revenue targets in 2026 and 2027.
- 07/26/2024
|
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. – ALIM
- NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Alimera Sciences, Inc . ( N asdaq: ALIM ), relating to its proposed merger with ANI Pharmaceuticals, Inc. Under the terms of the agreement, Alimera Sciences shareholders will receive $5.50 per share, and one contingent value right which shall represent the right to receive up to $0.50 per share contingent on reaching certain net revenue targets in 2026 and 2027.
- 07/03/2024
|
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. - ALIM
- NEW YORK , July 2, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Alimera Sciences, Inc. (Nasdaq: ALIM), relating to its proposed merger with ANI Pharmaceuticals, Inc. Under the terms of the agreement, Alimera Sciences shareholders will receive $5.50 per share, and one contingent value right which shall represent the right to receive up to $0.50 per share contingent on reaching certain net revenue targets in 2026 and 2027.
- 07/02/2024
|
SHAREHOLDER ALERT: Weiss Law Investigates Alimera Sciences, Inc.
- NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Alimera Sciences, Inc. ("Alimera" or the "Company") (NASDAQ:ALIM), in connection with its acquisition by ANI Pharmaceuticals, Inc. (NASDAQ: ANIP). Under the merger agreement, the Company's shareholders will receive $5.50per share in cash at closing and one non-tradable contingent value right ("CVR") to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027.
- 06/26/2024
|
Alimera (ALIM) Rises on Merger Deal With ANI Pharmaceuticals
- Alimera (ALIM) is set to be acquired by ANI Pharmaceuticals for approximately $381 million in upfront consideration. The transaction is expected to close in the third quarter of 2024.
- 06/25/2024
|
Dow Jumps 300 Points; Alimera Sciences Shares Spike Higher
- U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining more than 300 points on Monday.
- 06/24/2024
|
Shareholder Alert: Ademi LLP investigates whether Alimera Sciences, Inc. has obtained a Fair Price for its Public Shareholders
- MILWAUKEE , June 24, 2024 /PRNewswire/ -- Ademi LLP is investigating Alimera (Nasdaq: ALIM) for possible breaches of fiduciary duty and other violations of law in its transaction with ANI Pharmaceuticals. Click here to learn how to join the https://www.ademilaw.com/case/alimera-sciences-inc or call Guri Ademi toll-free at 866-264-3995.
- 06/24/2024
|
Why Is Alimera Sciences (ALIM) Stock Up 77% Today?
- Alimera Sciences (NASDAQ: ALIM ) stock is rocketing higher on Monday after the pharmaceutical company announced an acquisition deal with ANI Pharmaceuticals (NASDAQ: ANIP ). This agreement will have ANI Pharmaceuticals paying $5.50 per share for ALIM stock.
- 06/24/2024
|
ALIM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Alimera Sciences to ANI Pharmaceuticals
- MONSEY, N.Y., June 24, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”) to ANI Pharmaceuticals (“ANI”) for $5.50 per share in cash, plus a contingent value right (CVR) of $0.50 per share upon the achievement of certain net revenue milestones.
- 06/24/2024
|
Alimera Sciences stock rallies 75% on ANI Pharmaceuticals deal
- Alimera Sciences Inc (NASDAQ: ALIM) rallied a whopping 75% in premarket today after ANI Pharmaceuticals Inc (NASDAQ: ANIP) said it will buy the Alpharetta, Georgia based company for about $381 million. ANI shares are roughly flat at writing.
- 06/24/2024
|
ALIM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alimera Sciences, Inc. Is Fair to Shareholders
- NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Alimera Sciences, Inc. (NASDAQ: ALIM) to ANI Pharmaceuticals, Inc. for $5.50 per share in cash at closing and one non-tradable contingent value right representing the right to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027 is fair to Alimera shareholders. Halper Sadeh encourages Alimera shareholders to click here to learn more about t.
- 06/24/2024
|
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- ATLANTA, June 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced that, pursuant to Nasdaq Listing Rule 5635(c)(4) and in connection with the appointments of five non-executive employees, the Compensation Committee of the Board of Directors of the Company (the “Compensation Committee”) approved, on May 22, 2024 (the “Grant Date”), inducement awards consisting of stock options under the Alimera Sciences, Inc. 2024 Equity Inducement Plan to persons who were not previously employees or who rejoined the Company following a bona fide period of non-employment, as an inducement material to each such new or re-hired employee's employment (collectively, the “Inducement Awards”).
- 06/04/2024
|
Alimera Sciences, Inc. (ALIM) Q1 2024 Earnings Call Transcript
- Alimera Sciences, Inc. (NASDAQ:ALIM ) Q1 2024 Earnings Conference Call May 14, 2024 9:00 AM ET Company Participants Scott Gordon - CORE Investor Relations Rick Eiswirth - President and Chief Executive Officer Elliot Maltz - Chief Financial Officer Todd Wood - President U.S. Operations Philip Ashman - President, International Operations Conference Call Participants Chase Knickerbocker - Craig-Hallum Yi Chen - H.C. Wainwright & Company Naz Rahman - Maxim Group James Molloy - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by.
- 05/14/2024
|
Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates
- Alimera Sciences (ALIM) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.71 per share a year ago.
- 05/14/2024
|
Alimera Sciences Reports First Quarter 2024 Results
- ATLANTA, May 14, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the first quarter of 2024. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results.
- 05/14/2024
|
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network
- Protocol AL is studying ILUVIEN or faricimab (6.0 mg) injections versus observation for the prevention of visual acuity loss due to radiation retinopathy Protocol AL is studying ILUVIEN or faricimab (6.0 mg) injections versus observation for the prevention of visual acuity loss due to radiation retinopathy
- 03/19/2024
|
New Strong Sell Stocks for March 13th
- ASLE, ALIM and CADE have been added to the Zacks Rank #5 (Strong Sell) List on March 13, 2024.
- 03/13/2024
|
Alimera Sciences, Inc. (ALIM) Q4 2023 Earnings Call Transcript
- Alimera Sciences, Inc. (NASDAQ:ALIM ) Q4 2023 Earnings Conference Call March 7, 2024 9:00 AM ET Company Participants Scott Gordon - CORE Investor Relations Rick Eiswirth - President & Chief Executive Officer Elliot Maltz - Chief Financial Officer Todd Wood - President, U.S. Operations Conference Call Participants Alex Nowak - Craig-Hallum Capital James Molloy - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Alimera Sciences Fourth Quarter and Fiscal Year 2023 Financial Results and Corporate Update Conference Call.
- 03/07/2024
|
Alimera Sciences (ALIM) Reports Q4 Loss, Tops Revenue Estimates
- Alimera Sciences (ALIM) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.54 per share a year ago.
- 03/07/2024
|
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
- Q4 Net Revenues up 88% to $26.3 million vs. Q4 2022 2023 Net Revenues up 49% to $80.8 million vs. 2022 Increases 2024 Revenue Guidance
- 03/07/2024
|
The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®
- NICE Final Draft Guidance recommends providing National Health System (NHS) patients with a phakic lens access to the only sustained-release treatment lasting up to 36 months for chronic diabetic macular edema (DME) NICE Final Draft Guidance recommends providing National Health System (NHS) patients with a phakic lens access to the only sustained-release treatment lasting up to 36 months for chronic diabetic macular edema (DME)
- 02/08/2024
|
Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- ATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced that Elliot Maltz, C.P.A., has been named Chief Financial Officer effective immediately.
- 01/02/2024
|
Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- ATLANTA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced the appointment of Todd Wood as President U.S. effective immediately.
- 12/12/2023
|
Alimera Appoints Maggie A. Pax to Its Board of Directors
- ATLANTA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of Maggie A. Pax to its Board of Directors. Ms. Pax presently serves on the board of several life sciences companies.
- 11/08/2023
|
Alimera Sciences (ALIM) Reports Q3 Loss, Misses Revenue Estimates
- Alimera Sciences (ALIM) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.75 per share a year ago.
- 10/26/2023
|
Alimera Sciences Reports Third Quarter 2023 Results
- ATLANTA, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the third quarter of 2023. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results.
- 10/26/2023
|
Alimera Announces Multiple Presentations Highlighting ILUVIEN® and YUTIQ® Data at Retina Society Annual Congress
- ATLANTA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that clinical data for ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg and YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg will be featured in five presentations during the Retina Society's 56th Annual Scientific Meeting being held in New York City from October 11-14, 2023.
- 10/11/2023
|
Alimera Sciences Appoints Jason Werner as Chief Operating Officer
- ATLANTA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced the appointment of Jason Werner, Chief Operating Officer (“COO”), effective October 2, 2023. In conjunction with this appointment, Dr. Philip Ashman, previously Alimera's Chief Operating Officer and Senior Vice President, Commercial Operations Europe, was appointed President of International Operations.
- 10/03/2023
|
Alimera Sciences, Inc. (ALIM) Q2 2023 Earnings Call Transcript
- Alimera Sciences, Inc. (NASDAQ:ALIM ) Q2 2023 Earnings Conference Call August 10, 2023 9:00 AM ET Company Participants Scott Gordon - CORE IR Richard Eiswirth - President, CEO & Director Russell Skibsted - SVP & CFO Conference Call Participants Alexander Nowak - Craig-Hallum James Molloy - Alliance Global Partners Yi Chen - H.C. Wainwright & Co. Operator Ladies and gentlemen, thank you for standing by.
- 08/10/2023
|
Alimera Sciences (ALIM) Reports Q2 Loss, Lags Revenue Estimates
- Alimera Sciences (ALIM) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of $0.06. This compares to loss of $0.45 per share a year ago.
- 08/10/2023
|
Alimera Sciences Reports Second Quarter 2023 Results
- ATLANTA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the second quarter of 2023.
- 08/10/2023
|
Alimera Sciences to Report Second Quarter 2023 Financial Results on August 10, 2023, and Provide Corporate Update
- ATLANTA, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report second quarter financial results on August 10, 2023, prior to the market open. Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on corporate developments.
- 08/02/2023
|
Alimera Sciences (ALIM) Is Attractively Priced Despite Fast-paced Momentum
- If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Alimera Sciences (ALIM) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
- 06/08/2023
|
Are Medical Stocks Lagging Alimera Sciences (ALIM) This Year?
- Here is how Alimera Sciences (ALIM) and Haemonetics (HAE) have performed compared to their sector so far this year.
- 06/01/2023
|
Alimera (ALIM) Completes Enrollment in Eye Disease Study
- Alimera (ALIM) announces completion of patient enrollment in its NEW DAY study to evaluate Iluvien 0.19 mg as a baseline therapy in diabetic macular edema. The stock surges 8% on Wednesday.
- 05/25/2023
|
Alimera Sciences (ALIM) Shows Fast-paced Momentum But Is Still a Bargain Stock
- Alimera Sciences (ALIM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
- 05/23/2023
|
Alimera (ALIM) Up on Deal With Eyepoint for U.S. Rights to Yutiq
- Alimera Sciences ALIM announced acquiring additional U.S. commercialization rights for 0.18 mg dose strength of Yutiq from EyePoint Pharmaceuticals, Inc. Yutiq is indicated to treat chronic non-infectious uveitis affecting the posterior segment of the eye.
- 05/19/2023
|
How to Develop a Penny Stocks Trading Mentality
- Can these tips help you become a better penny stocks trader? The post How to Develop a Penny Stocks Trading Mentality appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/19/2023
|
Why Is Alimera Sciences (ALIM) Stock Up 21% Today?
- Alimera Sciences (NASDAQ: ALIM ) stock is taking off on Thursday after signing a major deal with EyePoint Pharmaceuticals (NASDAQ: EYPT ). That agreement has Alimera Sciences acquiring additional commercialization rights for YUTIQ from EyePoint Pharmaceuticals.
- 05/18/2023
|
Alimera Sciences (ALIM) Reports Q1 Loss, Tops Revenue Estimates
- Alimera Sciences (ALIM) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $0.85 per share a year ago.
- 05/15/2023
|
Alimera Sciences to Report First Quarter 2023 Financial Results on May 15, 2023, and Provide Corporate Update
- ATLANTA, May 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report first quarter financial results on May 15, 2023, prior to the market open. Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on corporate developments.
- 05/08/2023
|
Alimera Sciences (ALIM) Reports Q4 Loss, Misses Revenue Estimates
- Alimera Sciences (ALIM) delivered earnings and revenue surprises of -92.86% and 11.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/31/2023
|
Alimera Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 31, 2023, and Provide Corporate Update
- Conference Call to be held Friday, March 31, at 9:00am Eastern Time Conference Call to be held Friday, March 31, at 9:00am Eastern Time
- 03/24/2023
|
7 Stocks That Could Implode at Any Moment
- Although it's not a topic that everyone loves to hear, the concept of stocks to sell is a necessary one. Fundamentally, with fears of a global recession rising, investors need to start preparing for the worst.
- 11/17/2022
|
Alimera Sciences, Inc. (ALIM) Q3 2022 Earnings Call Transcript
- Alimera Sciences, Inc. (NASDAQ:ALIM ) Q3 2022 Results Conference Call November 14, 2022 9:00 AM ET Company Participants Scott Gordon - CORE, Investor Relations Rick Eiswirth - President & Chief Executive Officer Phil Jones - Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Laura Sorel - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Alimera Sciences Third Quarter 2022 Financial Results and Corporate Update Conference Call.
- 11/14/2022
|
Alimera Sciences (ALIM) Reports Q3 Loss, Lags Revenue Estimates
- Alimera Sciences (ALIM) delivered earnings and revenue surprises of -102.70% and 12.83%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/14/2022
|
Is Alimera Sciences (ALIM) Stock Outpacing Its Medical Peers This Year?
- Here is how Alimera Sciences (ALIM) and Deciphera Pharmaceuticals, Inc. (DCPH) have performed compared to their sector so far this year.
- 10/20/2022
|
Are Medical Stocks Lagging Alimera Sciences (ALIM) This Year?
- Here is how Alimera Sciences (ALIM) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.
- 09/19/2022
|
Why Fast-paced Mover Alimera Sciences (ALIM) Is a Great Choice for Value Investors
- Alimera Sciences (ALIM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
- 08/29/2022
|
Alimera Sciences (ALIM) Is a Great Choice for "Trend" Investors, Here's Why
- Alimera Sciences (ALIM) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
- 08/19/2022
|
Is Alimera Sciences (ALIM) Outperforming Other Medical Stocks This Year?
- Here is how Alimera Sciences (ALIM) and Centene (CNC) have performed compared to their sector so far this year.
- 08/17/2022
|
Alimera Sciences to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
- ATLANTA, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announced today that Rick Eiswirth, Alimera's President and Chief Executive Officer, will deliver a corporate presentation at the HC Wainwright 2nd Annual Ophthalmology Conference being held virtually on Wednesday, August 17, 2022.
- 08/10/2022
|
Here Is Why Bargain Hunters Would Love Fast-paced Mover Alimera Sciences (ALIM)
- Alimera Sciences (ALIM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
- 08/05/2022
|
Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q2 2022 Results - Earnings Call Transcript
- Alimera Sciences, Inc. (NASDAQ:ALIM ) Q2 2022 Earnings Conference Call July 27, 2022 9:00 AM ET Company Participants Scott Gordon - CORE, Investor Relations Rick Eiswirth - President & Chief Executive Officer Phil Jones - Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Yi Chen - H.C. Wainwright Operator Ladies and gentlemen, thank you for standing by.
- 07/30/2022
|
Alimera Sciences to Report Second Quarter 2022 Financial Results on Wednesday, July 27, 2022, and Provide Corporate Update
- Conference Call to be held Wednesday July 27, at 9:00am Eastern Time Conference Call to be held Wednesday July 27, at 9:00am Eastern Time
- 07/22/2022
|
Alimera Sciences, Inc (ALIM) CEO Richard Eiswirth on Q1 2022 Results - Earnings Call Transcript
- Alimera Sciences, Inc (NASDAQ:ALIM ) Q1 2022 Earnings Conference Call May 9, 2022 9:00 AM ET Company Participants Scott Gordon - CORE IR Richard Eiswirth - President and Chief Executive Officer Phil Jones - Chief Financial Officer Conference Call Participants Alexander Nowak - Craig-Hallum Capital Group James Molloy - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Alimera Sciences First Quarter 2022 Financial Results and Corporate Update Conference Call.
- 05/09/2022
|
Alimera Sciences to Report First Quarter 2022 Financial Results on Monday, May 9, 2022, and Provide Corporate Update
- Conference Call to be held the same day at 9:00am Eastern Time Conference Call to be held the same day at 9:00am Eastern Time
- 05/06/2022
|
New Strong Sell Stocks for April 26th
- ANIK, ALIM, and ADAP have been added to the Zacks Rank #5 (Strong Sell) List on April 26, 2022
- 04/26/2022
|
New Strong Sell Stocks for March 30th
- ALIM, APPF, and CNNE have been added to the Zacks Rank #5 (Strong Sell) List on March 30, 2022.
- 03/30/2022
|
New Strong Sell Stocks for March 28th
- ALIM, ANIK, and APPF have been added to the Zacks Rank #5 (Strong Sell) List on March 28, 2022
- 03/28/2022
|
New Strong Sell Stocks for March 1st
- AGIO, ALIM, and BV have been added to the Zacks Rank #5 (Strong Sell) List on March 1, 2022
- 03/01/2022
|
Alimera Sciences, Inc (ALIM) CEO Richard Eiswirth on Q4 2021 Results - Earnings Call Transcript
- Alimera Sciences, Inc (ALIM) CEO Richard Eiswirth on Q4 2021 Results - Earnings Call Transcript
- 02/24/2022
|
Alimera Sciences to Present at the MicroCap Rodeo Winter Wonderland Best Ideas Virtual Investor Conference
- ATLANTA, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces that Rick Eiswirth, Alimera's President and Chief Executive Officer will present at the MicroCap Rodeo Winter Wonderland Best Ideas Virtual Investor Conference, which is being held virtually from February 8 – 11, 2022.
- 02/04/2022
|
Alimera Sciences to Participate in Upcoming November 2021 Investor Conferences
- ATLANTA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that Rick Eiswirth, Alimera's President and Chief Executive Officer, will participate in three investor conference events in November.
- 11/09/2021
|
Alimera Sciences to Report Third Quarter 2021 Financial Results on Thursday, October 28, 2021, and Provide Corporate Update
- Conference Call to be held Thursday, October 28, 2021, at 9:00am Eastern Time Conference Call to be held Thursday, October 28, 2021, at 9:00am Eastern Time
- 10/21/2021
|
Analysts Estimate Alimera Sciences (ALIM) to Report a Decline in Earnings: What to Look Out for
- Alimera Sciences (ALIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/20/2021
|
ALIM Stock: Why It Increased Today
- The stock price of Alimera Sciences Inc (NASDAQ: ALIM) increased by over 6% today. This is why it happened.
- 10/13/2021
|
Recent 24-Month Real-World PALADIN Data Demonstrate the Ability of ILUVIEN® to Significantly Reduce Treatment Burden in Patients with Diabetic Macular Edema
- PALADIN Study Data Presented at the American Society of Retina Specialists Shows That Post-ILUVIEN, the Percentage of Eyes Receiving One Yearly Treatment or Less Increased 3.2-Fold Compared to Pre-ILUVIEN
- 10/13/2021
|
Alimera Sciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference
- ATLANTA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer., announces today that Chief Executive Officer Rick Eiswirth will present at the 23rd Annual H.C. Wainwright Global Investment Conference which is being held virtually from September 13 – 15, 2021.
- 09/02/2021
|
Alimera Sciences Announces National Pricing and Reimbursement Granted for ILUVIEN® for DME in Belgium
- ATLANTA, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, received pricing and reimbursement approval for ILUVIEN® for diabetic macular edema (DME) in Belgium from the National Institute for Health and Disability Insurance (INAMI). Pricing and reimbursement approval was sought and secured by Alimera's distribution partner in France and the Benelux region, Horus Pharma S.A.S. (Horus). Horus is currently in the launch phase in Belgium.
- 08/24/2021
|
New Strong Sell Stocks for August 19th
- ALIM, BEEM, CDR, ENTX, and IDEX have been added to the Zacks Rank #5 (Strong Sell) List on August 19, 2021.
- 08/19/2021
|
Alimera Sciences' (ALIM) CEO Rick Eiswirth on Q2 2021 Results - Earnings Call Transcript
- Alimera Sciences' (ALIM) CEO Rick Eiswirth on Q2 2021 Results - Earnings Call Transcript
- 08/14/2021
|
Alimera Sciences (ALIM) Q2 Earnings and Revenues Miss Estimates
- Alimera Sciences (ALIM) delivered earnings and revenue surprises of -39.20% and -6.85%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/13/2021
|
Recap: Alimera Sciences Q2 Earnings
- Shares of Alimera Sciences (NASDAQ:ALIM) moved higher by 5.3% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 252.94% year over year to $0.78, which missed the estimate of $1.06.
- 08/13/2021
|
Alimera Sciences Announces Second Quarter 2021 Financial Results
- ATLANTA, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, today announced financial results for the second quarter of 2021. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results.
- 08/13/2021
|
Alimera Sciences to Report Second Quarter 2021 Financial Results on Friday, August 13, 2021, and Provide Corporate Update
- Conference Call to be held Friday, August 13, 2021, at 9:00 am Eastern Time Conference Call to be held Friday, August 13, 2021, at 9:00 am Eastern Time
- 08/10/2021
|
Alimera Sciences, Inc. to Present at the Summer Solstice – Best Ideas from the Buy Side Conference on June 2, 2021
- ATLANTA, May 27, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that management has been invited to present at the Summer Solstice - Best Ideas from the Buy Side Conference, which is being held virtually on June 1 – June 4, 2021.
- 05/27/2021
|
Alimera Sciences Appoints David Dyer, M.D. as Chief Retina Specialist
- ATLANTA, May 17, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, has announced the expansion of its leadership team with the appointment of David Dyer, M.D. as chief retina specialist, effective today. Dr. Dyer brings his extensive medical knowledge and business expertise to the company, while continuing to see patients out of his longstanding practice in Kansas City, Missouri.
- 05/17/2021
|
Alimera Sciences Inc. (ALIM) CEO Rick Eiswirth on Q1 2021 Results - Earnings Call Transcript
- Alimera Sciences Inc. (ALIM) CEO Rick Eiswirth on Q1 2021 Results - Earnings Call Transcript
- 05/01/2021
|
Alimera Sciences (ALIM) Reports Q1 Loss, Lags Revenue Estimates
- Alimera Sciences (ALIM) delivered earnings and revenue surprises of -26.00% and -3.33%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 04/28/2021
|
Alimera Sciences Announces First Quarter 2021 Financial Results
- ATLANTA, April 28, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, today announced financial results for the first quarter of 2021. Alimera will host a conference call on April 29, 2021, at 9:00 a.m. ET to discuss these results.
- 04/28/2021
|
Week In Review: Sinopharm Transfers $4.6 Billion In Assets Including Two COVID-19 Vaccines
- Sinopharm, China's large state-owned pharma, will transfer six of its vaccine companies to Beijing Tiantan Biological Products, a Shanghai-listed biopharma that is 50% owned by Sinopharm. Shanghai's SciNeuro Pharma in-licensed Greater China rights to Lilly's alpha-synuclein targeted antibody therapies, an expected therapy for Parkinson's.
- 04/18/2021
|
Alimera Sciences to Present at the Zooming with LD Micro Virtual Conference on April 15, 2021
- ATLANTA, April 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announced that Rick Eiswirth, President and Chief Executive Officer, will give a corporate presentation at the Zooming with LD Micro virtual conference on Thursday, April 15, 2021 at 11:00 AM ET followed by a live Q&A session with registered investors and other conference attendees. In addition, Mr. Eiswirth will be available for virtual one-on-one meetings the same day.
- 04/09/2021
|
Alimera Sciences to Present at the H.C. Wainwright Global Life Sciences Conference
- ATLANTA, March 02, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that President and CEO Rick Eiswirth will present at the H.C. Wainwright Global Life Sciences Conference to be held on March 9-10, 2021.
- 03/02/2021
|
Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q4 2020 Results - Earnings Call Transcript
- Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q4 2020 Results - Earnings Call Transcript
- 02/27/2021
|
Alimera Sciences Reports Fourth Quarter and 2020 Results
- Fourth Quarter Highlights:
- 02/24/2021
|
Alimera Sciences Continues Global Geographic Expansion With Launch of ILUVIEN in Finland for Both Indications
- ATLANTA, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, announces that ILUVIEN is now available in Finland for diabetic macular edema (DME) and non-infectious uveitis affecting the posterior segment (NIPU), and will be marketed by Alimera and distributed by Nordic Prime.
- 02/18/2021
|
Alimera Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 24, 2021 and Provide Corporate Update
- Conference Call to be held Thursday, February 25, 2021 at 9:00am Eastern Time Conference Call to be held Thursday, February 25, 2021 at 9:00am Eastern Time
- 02/17/2021
|
Alimera Sciences to Present at the Microcap Rodeo Winter Wonderland Conference
- ATLANTA, Feb. 15, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that President and CEO Rick Eiswirth will present at the Microcap Rodeo Winter Wonderland Conference, which will be held from February 16-19, 2021.
- 02/15/2021
|
Alimera Sciences, Inc. Discusses Its 2021 Global Expansion Strategy with The Stock Day Podcast
- Phoenix, Arizona--(Newsfile Corp. - February 1, 2021) - The Stock Day Podcast welcomed Alimera Sciences, Inc. (NASDAQ: ALIM) ("the Company"), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. President and CEO of the Company, Rick Eiswirth, joined Stock Day host Everett Jolly. Jolly began the interview by asking about the Company's background and current projects. "We are an ophthalmology company, so we're focused on finding ways to treat diseases...
- 02/01/2021
|
Alimera Sciences Announces Preliminary Top-line Results for Fourth Quarter and Full-Year 2020
- ATLANTA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, announces preliminary consolidated net revenue for the fourth quarter of 2020 in excess of $13.5 million and annual 2020 consolidated net revenue in excess of $50.5 million. Alimera anticipates that cash on December 31, 2020 will be $11.2 million compared to $11.3 million on September 30, 2020.
- 01/19/2021
|
Alimera Sciences to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference
- ATLANTA, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that President and CEO Rick Eiswirth will present at the H.C. Wainwright Bioconnect 2021 Virtual Conference taking place January 11-14, 2021.
- 01/05/2021
|
Alimera Sciences Announces Launch of ILUVIEN® in the Netherlands
- ILUVIEN has been launched for both Diabetic Macular Edema and Non-Infectious Posterior Uveitis Indications ILUVIEN has been launched for both Diabetic Macular Edema and Non-Infectious Posterior Uveitis Indications
- 12/09/2020
|
Alimera Sciences to Present at the 13th Annual LD Micro Main Event Virtual Conference
- ATLANTA, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that CEO Rick Eiswirth will present a corporate overview at the 13th Annual LD Micro Main Event virtual investor conference on Monday, December 14 at 8:20 AM PST/11:20 AM EST. The format will be a 10-minute presentation followed by a 10-minute Q&A session with a panel of investors and analysts.
- 12/08/2020
|
Alimera Sciences Announces Participation at the 11th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 17, 2020
- ATLANTA, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that Rick Eiswirth, Alimera's President and Chief Executive Officer, will participate in the Craig-Hallum Capital Group's annual Alpha Select Conference on Tuesday November 17, 2020. The conference consists of one-on-one and small group meetings, which will take place via video conference.
- 11/16/2020
|
Alimera Sciences Announces Third Quarter 2020 Financial Results
- Rebound Continues from COVID Challenges Rebound Continues from COVID Challenges
- 10/28/2020
|
Trump's New Iran Sanctions Might Not Kill the Nuclear Deal, But They Will Hurt the U.N.
- Secretary of State Mike Pompeo is reportedly heading to New York to invoke 'snapback' provisions of the Iran nuclear deal. It's an act of diplomatic vandalism.
- 08/19/2020
|
Alimera Sciences Signs Distribution Agreement With Nordic Prime to Expand International Sales of ILUVIEN® Into Nordic Countries
- ATLANTA, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, today announced that its Ireland-based European subsidiary, Alimera Sciences Europe Limited, has signed a distribution agreement with Nordic Prime ApS to serve as Alimera’s distribution partner in Denmark, Finland, Norway and Sweden for ILUVIEN® 190 micrograms intravitreal implant in applicator. ILUVIEN is approved in these territories for the treatment of vision impairment associated with chronic diabetic macular edema considered insufficiently responsive to available therapies and for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. Under the Agreement, Nordic Prime will engage in hospital tendering activities to secure purchasing agreements of ILUVIEN across the Nordic region and is responsible for shipping of orders and maintaining all back-office support for Nordic customers.“We continue to advance our strategy of geographically expanding the availability of ILUVIEN into additional countries to increase our global market share and sales,” said Rick Eiswirth, President and Chief Executive Officer of Alimera. “Working with Nordic Prime enables us to supply ILUVIEN to hospitals and physicians in the Nordic region of Europe, where more than 100,000 patients are estimated to suffer from either diabetic macular edema or non-infectious posterior uveitis.” “We are extremely pleased to be a part of Alimera’s strategic commercial expansion in the Nordic European countries,” said Patricio Aguirre, Managing Director of Nordic Prime. “We believe ILUVIEN’s ability to control the recurrence of debilitating retinal diseases and improve patients’ vision with fewer injections, will provide significant benefits to Nordic physicians and their patients.”About ILUVIENwww.ILUVIEN.comAlimera’s primary product is ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant, injected into the back of the eye. With its CONTINUOUS MICRODOSING™ Delivery technology, ILUVIEN is designed to release sub-microgram levels of fluocinolone acetonide, a corticosteroid, for 36 months, to reduce the recurrence of disease, enabling patients to maintain vision longer with fewer injections. ILUVIEN is approved in the U.S., Canada, Kuwait, Lebanon and the U.A.E to treat diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. In 17 European countries, ILUVIEN is indicated for the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies. In March 2019, ILUVIEN received approval in the 17 countries under the Mutual Recognition Procedure for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The 17 European countries include the U.K., Germany, France, Italy, Spain, Portugal, Ireland, Austria, Belgium, Denmark, Norway, Finland, Sweden, Poland, Czechia, the Netherlands, and Luxembourg. The non-infectious posterior uveitis indication for ILUVIEN was launched in Germany and the U.K. in 3Q 2019. ILUVIEN is not approved for treatment of uveitis in the United States.About Diabetic Macular Edema (DME)DME, the primary cause of vision loss associated with diabetic retinopathy, is a disease affecting the macula, the part of the retina responsible for central vision. When the blood vessel leakage associated with diabetic retinopathy results in swelling of the macula, the condition is called DME. The onset of DME is painless and may go unreported by the patient until it manifests with the blurring of central vision or acute vision loss. The severity of this blurring may range from mild to profound loss of vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy found that over a 10-year period approximately 19% of people with diabetes included in the study were diagnosed with DME. All people with type 1 or type 2 diabetes are at risk of developing DME.About Non-Infectious Posterior Uveitis (NIPU)Posterior segment non-infectious uveitis is a chronic, inflammatory disease affecting the posterior segment of the eye, often involving the retina, and is a leading cause of blindness in developed and developing countries. It affects people of all ages, producing swelling and destroying eye tissues, which can lead to severe vision loss and blindness. Patients with NIPU are typically treated with systemic steroids, which are effective, but over time frequently lead to serious side effects, ranging from acne, weight gain, sleep and mood disorders to hypertension and osteoporosis that can limit effective dosing. Patients then often progress to steroid-sparing therapy with systemic immune suppressants or biologics, which also can have severe side effects, including an increased risk of cancer and infection. As a result, there remains a significant need for new therapies with improved efficacy, tolerability, and safety profiles to manage this disease.About Alimera Sciences, Inc.www.alimerasciences.comAlimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations. For more information, please visit www.alimerasciences.com.About Nordic PrimeNordic Prime is a private owned Danish pharmaceutical distributor, selling to pharmacies and hospitals within the Nordic region. http://www.nordicprime.dk/Forward Looking StatementsThis press release contains “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, Alimera’s expectations with respect to access to ILUVIEN for Nordic hospitals and patients. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in its forward-looking statements. Meaningful factors which could cause actual results to differ include, but are not limited to, Nordic Prime’s ability to launch ILUVIEN in the Nordic countries, Nordic Prime’s ability to successfully obtain tender business for ILUVIEN, the acceptance by physicians in the Nordic countries of ILUVIEN for use with DME and posterior uveitis patients, as well as other factors discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Alimera’s Annual Report on Form 10-K for the year ended December 31, 2019 and Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020 and June 30, 2020, which are on file with the Securities and Exchange Commission (SEC) and available on the SEC’s website at www.sec.gov.All forward-looking statements contained in this press release are expressly qualified by the cautionary statements contained or referred to herein. Alimera cautions investors not to rely too heavily on the forward-looking statements Alimera makes or that are made on its behalf. These forward-looking statements speak only as of the date of this press release (unless another date is indicated). Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.For press inquiries: Jules Abraham for Alimera Sciences 917-885-7378 julesa@coreir.comFor investor inquiries: Scott Gordon for Alimera Sciences scottg@coreir.com
- 08/13/2020
|
Up to 750,000 UK Covid test kits recalled due to safety concerns
- Products made by diagnostics firm Randox removed from care homes and individuals
- 08/08/2020
|
Abu Dhabi's Etihad Airways posts $758M in half-year losses
- Abu Dhabi’s Etihad Airways says core operating losses amounted to $758 million for the first half of the year, driven by a nearly 40% drop in revenue due in part to the impact of the coronavirus pandemic
- 08/06/2020
|
What Makes Alimera Sciences (ALIM) a New Strong Buy Stock
- Alimera Sciences (ALIM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
- 08/05/2020
|
New Strong Buy Stocks For August 5th
- New Strong Buy Stocks For August 5th
- 08/05/2020
|
LD Micro Announces Preliminary List of Presenters for the LD 500
- LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
- 08/05/2020
|
MyoKardia Heart Trial, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:MYOK)
- MyoKardia reports initiating trial for invasive septal reduction therapy. Aileron completes enrollment in chemotherapeutic agent trial.
- 08/04/2020
|
AP PHOTOS: Muslims worldwide mark Eid festival amid pandemic
- Muslims worldwide have marked the Eid al-Adha holiday amid a global pandemic that has impacted nearly every aspect of this year’s celebrations
- 08/02/2020
|
Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q2 2020 Results - Earnings Call Transcript
- Alimera Sciences, Inc. (NASDAQ:ALIM) Q2 2020 Earnings Conference Call July 30, 2020, 09:00 AM ET Company Participants Scott Gordon - President, CORE IR Rick Eiswirth - President and CEO Phil Jones - CFO Conference Call Participants Alex Nowak - Craig-Hallum Capital Group James Molloy - Alliance Global Partners Yi Chen - HC Wainwright Presentation Operator Ladies and gentlemen, thank you for standing by.
- 08/02/2020
|
Libyans fear regional war as rival powers vie for control, says envoy
- UN envoy has two months to secure ceasefire but warns that risks are rising
- 08/01/2020
|
Alimera Sciences Inc (ALIM) Q2 2020 Earnings Call Transcript
- Image source: The Motley Fool. Alimera Sciences Inc (NASDAQ: ALIM)Q2 2020 Earnings CallJul 30, 2020, 1:00 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorLadies and gentlemen, thank you for standing by.
- 07/31/2020
|
Opinion | A Space Race for the 21st Century
- China aims to land a Mars rover, something the EU hasn’t managed.
- 07/30/2020
|
'On our way to Mars': NASA rover will look for signs of life
- The biggest, most sophisticated Mars rover ever built is on its way to the red planet
- 07/30/2020
|
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 29)
Abbott Laboratories (NYSE: ABT)
ABIOMED, Inc. (NASDAQ: ABMD)
Adamis Pharmaceuticals Corp (NASDAQ: ADMP)
Annexon...
- 07/30/2020
|
Alimera Sciences (ALIM) Reports Q2 Loss, Tops Revenue Estimates
- Alimera Sciences (ALIM) delivered earnings and revenue surprises of 76.17% and 336.44%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 07/29/2020
|
Recap: Alimera Sciences Q2 Earnings
- Shares of Alimera Sciences (NASDAQ:ALIM) decreased 1.5% after the company reported Q2 results.Quarterly Results Earnings per share fell 628.57% year over year to ($0.51), which beat the estimate of ($1.44).Revenue of $10,038,000 declined by 7.53% year over year, which beat the estimate of $6,940,000.Outlook Alimera Sciences hasn't issued any earnings guidance for the time being.View more earnings on ALIMRevenue guidance hasn't been issued by the company for now.Price Action 52-week high: $9.9852-week low: $0.00Price action over last quarter: Up 12.13%Company Overview Alimera Sciences Inc is a pharmaceutical company. It specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. The product portfolio of the company includes ILUVIEN, which is developed to treat diabetic macular edema. In addition, to the activities related to the development of ILUVIEN, the group is also researching the safety and effectiveness of NADPH (Nicotinamide Adenine Dinucleotide Phosphate) oxidase inhibitors. Geographically it operates through the region of US and also it has its presence in the international market.See more from Benzinga * Recap: MYR Group Q2 Earnings * Transocean: Q2 Earnings Insights * PayPal Holdings: Q2 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 07/29/2020
|
Alimera Sciences Announces Second Quarter 2020 Financial Results and Provides Corporate Update
- Second Quarter and Recent Company Highlights: * Consolidated Net Revenue Down 8% Compared to Second Quarter 2019 * International Net Revenue Up 89% Compared to Second Quarter 2019 * Net Loss of $2.5 Million vs. $5.0 Million in Second Quarter 2019 * Adjusted EBITDA Loss of $0.3 Million vs. $2.1 Million in Second Quarter 2019ATLANTA, July 29, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces financial results for the three months ended June 30, 2020. Alimera will host a conference call on Thursday, July 30, 2020 at 9:00 AM ET to review these financial results and provide an update on corporate developments.“The second quarter of 2020 was a successful quarter for Alimera Sciences in the context of the COVID-19 pandemic, having delivered $10 million in revenue, decreasing only 8% versus the second quarter of 2019, despite limited access to patients. We leveraged our geographic diversity and the late 2019 European launch of ILUVIEN for uveitis while managing our expenses. These results led to improvements in net loss and adjusted EBITDA compared to the second quarter of 2019,” said Rick Eiswirth, Alimera’s President and Chief Executive Officer. “As we move through the COVID-19 pandemic, we believe that physicians will see ILUVIEN in a new light. Having not made any changes to our staffing levels across the organization, we believe we are positioned to communicate how ILUVIEN provides significant long-term clinical benefits while reducing the number of visits for high-risk patients. ILUVIEN can also help doctors work through their backlog of patients who have been left untreated or undertreated during the pandemic.”Second Quarter 2020 Financial ResultsNet Revenue Consolidated net revenue for Q2 2020 was down 8% to $10.0 million, compared to $10.9 million for Q2 2019.U.S. net revenue was $3.4 million for Q2 2020, down 53% from $7.3 million during the same period in 2019. End user demand, which represents units purchased by physicians and pharmacies from Alimera’s U.S. distributors, was 625 units in Q2 2020 compared to 917 units in Q2 2019, a decrease of 32%, as a result of lower demand due to COVID-19. Additionally, our distributors lowered their inventory levels and purchased approximately 36% fewer units than they sold to end users as weekly volumes decreased in the second quarter due to COVID-19.International net revenue increased 89% to approximately $6.6 million in Q2 2020, compared to approximately $3.5 million for the same period during 2019, driven primarily by increasing sales behind the posterior uveitis indication in the U.K. and Germany and by increased business in our distributor markets.Operating Expenses Total operating expenses for Q2 2020 decreased by $3.4 million or 26% to $9.9 million, compared to $13.3 million during Q2 2019. Alimera achieved major expense reductions by reducing travel costs, decreasing attendance at medical conferences that were cancelled or converted to virtual meetings and reducing its spending on external commercial and medical activities.Net Loss and Non-GAAP Adjusted EBITDA For Q2 2020, Alimera reported a net loss of approximately $2.5 million, compared to a net loss of $5.0 million for Q2 2019. “Adjusted EBITDA,” a non-GAAP financial measure defined below, was a loss of approximately $0.3 million for Q2 2020, compared to a loss of approximately $2.1 million for Q2 2019.Net Loss per Share Basic and diluted net loss per share for Q2 2020 was $(0.51). This compares to basic and diluted net loss per share for Q2 2019 of $(1.06).Cash and Cash Equivalents As of June 30, 2020, Alimera had cash and cash equivalents of approximately $13.5 million, compared to $12.2 million in cash and cash equivalents as of March 31, 2020.Definition of Non-GAAP Financial Measure For purposes of this press release, “Adjusted EBITDA” is defined as earnings before interest, taxes, depreciation, amortization, stock-based compensation expenses, net unrealized gains and losses from foreign currency exchange transactions, losses on extinguishment of debt and severance expenses. Please refer to the sections of this press release entitled “Non-GAAP Financial Measure” and “Reconciliation of GAAP Net Loss to Non-GAAP Adjusted EBITDA.”Conference Call to Be Held July 30, 2020 Management will host a conference call at 9:00 AM ET on Thursday, July 30, 2020, to review financial results and provide an update on corporate developments. Following management’s formal remarks, there will be a question and answer session.Participants are asked to pre-register for the call through the following link: http://dpregister.com/10145768. Please note that registered participants will receive their dial in number upon registration and will dial directly into the call without delay. Those without internet access or unable to pre-register may dial in by calling: 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Alimera Sciences call. The conference call will also be available through a live webcast, which can be accessed through the following link: https://services.choruscall.com/links/alimera200730.html, which is also available through the company’s website at https://investors.alimerasciences.com/ALIM/events/3819.A webcast replay of the call will be available approximately one hour after the end of the call through October 30, 2020. The replay can be accessed through the above links or by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code 10145768. The telephonic replay will be available until August 13, 2020.About Alimera Sciences, Inc.www.alimerasciences.comAlimera is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people globally. For more information, please visit www.alimerasciences.com.Non-GAAP Financial MeasureThis press release contains a discussion of a non-GAAP financial measure, as defined in Regulation G promulgated under the Securities Exchange Act of 1934, as amended. Alimera reports its financial results in compliance with GAAP but believes that the non-GAAP measure of Adjusted EBITDA provides useful information to investors regarding Alimera’s operating performance. Alimera uses Adjusted EBITDA in the management of its business. Accordingly, Adjusted EBITDA for the three and six months ended June 30, 2020 has been presented in certain instances excluding items identified in the reconciliations provided in the table entitled “Reconciliation of GAAP Net Loss to non-GAAP Adjusted EBITDA.” GAAP net loss is the most directly comparable GAAP financial measure to Adjusted EBITDA. Adjusted EBITDA, as presented, may not be comparable to similarly titled measures reported by other companies because not all companies may calculate Adjusted EBITDA in an identical manner. Therefore, Adjusted EBITDA is not necessarily an accurate measure of comparison between companies.The presentation of Adjusted EBITDA is not intended to be considered in isolation or as a substitute for guidance prepared in accordance with GAAP. The principal limitation of this non-GAAP financial measure is that it excludes significant elements required by GAAP to be recorded in Alimera’s financial statements. In addition, Adjusted EBITDA is subject to inherent limitations as it reflects the exercise of judgments by management in determining this non-GAAP financial measure.About ILUVIENILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant, injected into the back of the eye. With its CONTINUOUS MICRODOSING™ technology, ILUVIEN is designed to release submicrogram levels of fluocinolone acetonide, a corticosteroid, for up to 36 months, to reduce the recurrence of disease. ILUVIEN enables patients to maintain vision longer with fewer injections. ILUVIEN is approved in the U.S., Canada, Kuwait, Lebanon and the U.A.E. to treat diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. In 17 European countries, ILUVIEN is indicated for the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies and for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIPU). Alimera does not have the contractual right to pursue approval to treat uveitis in the U.S., and therefore does not have a regulatory license in the U.S. to treat NIPU. For important safety information on ILUVIEN, see: https://iluvien.com/isiForward Looking StatementsThis press release contains, and the remarks by Alimera’s officers on the conference call may contain, “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, Alimera’s expectations with respect to (a) how physicians will view ILUVIEN in light of current circumstances, and (b) Alimera being positioned to communicate how ILUVIEN provides significant long-term clinical benefits while reducing the number of visits for high-risk patients.
- 07/29/2020
|
Iran missiles target fake carrier as US bases go on alert
- Iran’s paramilitary Revolutionary Guard has launched missiles targeting a mock aircraft carrier in the strategic Strait of Hormuz
- 07/29/2020
|
The Daily Biotech Pulse: Merck's Breakthrough Therapy Designation, Sonoma Surges On Sanitizer News, Sanofi-Glaxo And More
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 28)
Axonics Modulation Technologies Inc (NASDAQ: AXNX)
Capricor Therapeutics Inc (NASDAQ: CAPR)
Fulgent Genetics Inc...
- 07/29/2020
|
Iran moves mock aircraft carrier to sea amid US tensions
- Iran has moved a mock aircraft carrier to the strategic Strait of Hormuz amid heightened tensions between Tehran and Washington
- 07/27/2020
|
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
- Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Although there were promising updates from...
- 07/26/2020
|
Frozen pensions: injustices faced by Windrush generation in spotlight
- Campaigners urge new working group to look into why some retirees living abroad are penalised
- 07/25/2020
|
Alimera (ALIM) to Report Q2 Earnings: What's in the Cards?
- Alimera (ALIM) will provide updates on its corporate developments during the second-quarter 2020 earnings release.
- 07/23/2020
|
Alimera Sciences to Report Second Quarter 2020 Financial Results on Wednesday, July 29, 2020 and Provide Corporate Update
- Conference Call to be held Thursday, July 30, 2020 at 9:00 AM Eastern TimeATLANTA, July 22, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it will report second quarter 2020 financial results on Wednesday, July 29, 2020 after the market close. Management will host a conference call at 9:00 AM ET on Thursday, July 30, 2020, to review financial results and provide an update on corporate developments. Following management’s formal remarks, there will be a question and answer session.Participants are asked to pre-register for the call through the following link: http://dpregister.com/10145768. Please note that registered participants will receive their dial in number upon registration and will dial directly into the call without delay. Those without internet access or unable to pre-register may dial in by calling: 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Alimera Sciences call. The conference call will also be available through a live webcast, which can be accessed through the following link: https://services.choruscall.com/links/alimera200730.html, which is also available through the company’s website at https://investors.alimerasciences.com/ALIM/events/3819.A webcast replay of the call will be available approximately one hour after the end of the call through August 13, 2020. The replay can be accessed through the above links or by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code 10145768. The telephonic replay will be available until August 13, 2020.About Alimera Sciences, Inc.Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations. For more information, please visit www.alimerasciences.com.For press inquiries: Jules Abraham for Alimera Sciences 917-885-7378 julesa@coreir.comFor investor inquiries: Scott Gordon for Alimera Sciences scottg@coreir.com
- 07/22/2020
|
Total S.A. UK Regulatory Announcement: TOTAL becomes a European Company
- TOTAL S.A. (Paris:FP) (LSE:TTA) (NYSE:TOT) announces that it has become TOTAL SE following its registration with the Trade and Companies Register of
- 07/20/2020
|
Boris Johnson knows how to win. To survive a second year he must learn how to govern | Stephen Bush
- The prime minister is long on platitudes and short on policies, and Keir Starmer is stalking him in the polls
- 07/19/2020
|
Basilea continues with the implementation of the Repurchase Offer and the issuance of New Bonds | MarketScreener
|
TOTAL becomes a European Company
- Regulatory News: TOTAL S.A. (Paris:FP) (LSE:TTA) (NYSE:TOT) announces that it has become TOTAL SE following its registration with the Trade and Compan
- 07/17/2020
|
Binance’s Swipe-Powered Crypto Debit Card Debuts in Europe
- Binance’s Swipe-Powered Crypto Debit Card Debuts in Europe
- 07/14/2020
|
Outlook of Diabetic Macular Edema (DME) 2020-2025 - Current Landscape and the Way Forward - ResearchAndMarkets.com
|
Alimera Sciences Initiates Landmark NEW DAY Clinical Trial to Evaluate ILUVIEN® as Baseline Therapy for Diabetic Macular Edema
- A randomized, controlled, multi-center study designed to demonstrate better disease control, reduced retinal damage and a reduction in treatment frequency compared to current.
- 07/09/2020
|
Online rules for the PS4 Pro and F1 2020 competition in polls on The Sun
- SONY PS4 PRO AND F1 2020 COMPETITION ON THE SUN ONLINE (THE “PROMOTION”) ONLINE RULES: By entering the Promotion, you agree to be bound by these terms and conditions (these Terms and Co…
- 07/02/2020
|
COVID19: EU gives Cyprus go-ahead to attract airlines - Financial Mirror
- Brussels has given Nicosia the green light to help out coronavirus-struck airlines flying to Cyprus with a €6.3 mln incentive scheme. The Ministry of Transport announced on Thursday that the state incentive scheme was approved under the European Commission’s state aid temporary framework. Under the scheme, Cyprus will be giving out each company direct grants
- 07/02/2020
|
Post-Brexit immigration plans could halve migrant workers, report warns - Evening Express
- Immigration into Scotland could be halved by the proposed salary threshold and risks staff shortages in areas such as the care sector, a study has found.
- 07/02/2020
|
Post-Brexit immigration plans could halve migrant workers, report warns - Evening Telegraph
- Immigration into Scotland could be halved by the proposed salary threshold and risks staff shortages in areas such as the care sector, a study has found.
- 07/02/2020
|
Survey shows patients wait six times longer than EU neighbours for new drugs -
- Patients in some European countries are waiting up to six times longer for access to medicines than their neighbours, according to a survey by Europe’s pharma trade body.
- 07/02/2020
|
Nicola Sturgeon’s SNP project derailed as EU’s devastating verdict on membership laid bare
- NICOLA STURGEON has pleaded with Europe's leaders to join the EU - but her plans were comprehensively rejected by the bloc, leaving the SNP's entire political project in tatters.
- 07/02/2020
|
2020 Study into the Global Macular Edema Industry - Market Size and Drug Sales - ResearchAndMarkets.com
|
Get up to 40% off beauty brands - from Benefit to IT Cosmetics
- TO celebrate a new look Fab Daily in the Sun newspaper this week, some of our favourite beauty brands are offering discounts to readers… benefitcosmetics.com – 15% off with the cod…
- 07/01/2020
|
Don't Nod Entertainment :
DONTNOD LAUNCHES A CAPITAL INCREASE TO CONSOLIDATE ITS POSITION IN THE VIDEO GAMES SECTOR | MarketScreener
|
Most EU Countries Remain Closed to Serbia, Montenegro | Balkan Insight
- Most EU states will not yet reopen their borders to nationals from Serbia and Montenegro, although the EU Council on Tuesday recommended Member States to lift restrictions on entry from 15 listed countries, including these two.
- 07/01/2020
|
EU fisheries outrage: Warning of ‘300-boat invasion’ in UK waters day after no deal Brexit
- THE EUROPEAN UNION is desperate to maintain access to British fishing grounds - so much so that one startling report warned of a near 300-boat invasion into UK waters if a no deal Brexit scenario occurs.
- 07/01/2020
|
Conversion of paid subscribed units (BTU) to shares and warrants of series 2021
|
‘I was so fascinated by life sciences that I refused to go to dental school’
- Nidhi Kedia-Mehta seemed set to study dentistry, but encountering biotech and life sciences opened a new world for her.
- 07/01/2020
|
101Investing: A New Broker With Over 250 CDF Instruments And Up To 500X Leverage!
- A tier-one broker offering over 250 CDFs in five major categories including precious metals, stocks, index funds, cryptocurrencies, and forex 101Investing is a trade broker is a subsidiary of FXBFI Broker Financial Invest Ltd, an investment firm headquartered in Cyprus. The offers traders a wide spread of CDF instruments on its trading platforms such as
- 06/30/2020
|
Nicola Sturgeon's 'embarrassing' plan to keep Scotland in single market exposed
- NICOLA STURGEON was accused of dragging her country into an "embarrassing mess", after it emerged that she had unveiled a report that strongly warned against her plan to keep Scotland in the EU's single market, unearthed reports reveal.
- 06/30/2020
|
Nicola Sturgeon humiliation: Spain's rejection of 'dishonest' SNP plan to join EU exposed
- NICOLA STURGEON was furious when the UK voted to leave the EU amid Brexit - but her efforts to get Scotland back in the bloc suffered an immediate blow.
- 06/30/2020
|
Telenor : to Appeal $126 Million European Free Trade Association Fine | MarketScreener
|
AEX Gold Inc. Intends to Seek Admission to Trading on AIM and Proposed Placing to Raise £45 Million | | IT Business Net
- This announcement is not for release, publication or distribution, directly or indirectly, in whole or in part, in or into the United States, Australia, Japan, South Africa or any other jurisdiction i
- 06/30/2020
|
Thug jailed for role in torture of Lincs man deported by private jet
- 'They were tipping water over my face. I couldn't breathe. I was panicking'
- 06/30/2020
|
Pfenex : Adalvo announces positive CHMP opinion for Livogivatm (Teriparatide injection) | MarketScreener
|
Cosmo Pharmaceuticals N : receives positive EMA CHMP Opinion recommending approval of Methylene Blue MMX for the visualization of colorectal lesions during colonoscopies | MarketScreener
|
Wirecard : Pakistani Freelancers' Millions of Dollars Stuck Due to Payoneer Transactions Frozen | MarketScreener
|
Tiktok to transfer data control to UK arm ahead of Brexit - CityAM
- Tiktok has said it will be moving ownership of its users' data in Europe to local subsidiaries, in a boost to its British arm as it prepares for Brexit.
- 06/29/2020
|
Do something! Boris urged to act as fishermen stranded - 'Shouldn't be treated this way'
- CONCERNS have been raised over migrant fisherman being confined to their fishing boats because they are unable to access support due to their immigration status.
- 06/29/2020
|
Now your business can have a Monzo account - what's on offer?
- Challenger bank Monzo, which already boasts more than two million customers for its personal offering, has launched a business account designed to help small businesses keep track of their finances.
- 06/29/2020
|
Rourkela Steel Plant bags over 6,000-tonne of plates order for European market
- Amid sluggish market scenario across the world due to the COVID-19 crisis, the Rourkela Steel Plant, a unit of state-run SAIL, on Sunday said it has bagged an order of over 6,000 tonne of special grade plates for supplying to the European market.
- 06/28/2020
|
Wirecard : Millions of dollars belonging to Pakistani freelancers stuck indefinitely amid Wirecard fraud | MarketScreener
|
EU loophole sees three criminals jailed for rape and torture deported
- A violent thug and two rapists have been deported back to Lithuania after finishing their prison terms in the UK. Home Secretary Priti Patel used was able to deport them on public security grounds.
- 06/28/2020
|
That Clayton Barnes is still not a citizen shows the ongoing cruelty of ‘hostile environment’ | Kenan Malik
- Just how long will it take for the lessons of Windrush to be learned?
- 06/28/2020
|
Norway to Ease Travel Restrictions for Europe, Keeps Sweden Out - BNN Bloomberg
- Norway is continuing to ease travel restrictions to and from the rest of Europe, but is still recommending that its citizens avoid areas with high Covid-19 rates, including neighboring Sweden.
- 06/25/2020
|
New Strong Buy Stocks For June 25th
- New Strong Buy Stocks For June 25th
- 06/25/2020
|
*Harmony Gold Mining Company Limited – RESULTS OF PLACING - SENS
- Sens announcement for *Harmony Gold Mining Company Limited – RESULTS OF PLACING - SENS
- 06/25/2020
|
HARMONY GOLD MINING COMPANY LIMITED – Results of placing - SENS
- Sens announcement for HARMONY GOLD MINING COMPANY LIMITED – Results of placing - SENS
- 06/25/2020
|
Regeneron Pharmaceuticals : to Vigorously Defend Allegations Related to Contributions to a Patient Assistance Charity in 2013 and Early 2014 | MarketScreener
|
Extend Indian Medics' Visas Fee-Free: UK Doctors' Body To Priti Patel
- Britain's leading doctors' associations are calling on UK Home Secretary Priti Patel for an automatic fee-free extension of the short-term visas of many Indian doctors stranded in the lockdown as they await their international qualification exams in the UK.
- 06/24/2020
|
Fears government plans to rehouse rough sleepers will force thousands back on to streets due to immigration status
- ‘Coronavirus does not discriminate on grounds of visa status and nor must public health measures,’ says charity
- 06/24/2020
|
UK Home Secretary Under Pressure to Extend Indian Doctors' Visas Till End-2020
- The British Medical Association (BMA) and British Association of Physicians of Indian Origin (BAPIO) issued a joint letter to the minister on Tuesday to highlight the plight of around 220 overseas doctors, many of them from India.
- 06/24/2020
|
HARMONY GOLD MINING COMPANY LIMITED – Proposed placement of new ordinary shares - SENS
- Sens announcement for HARMONY GOLD MINING COMPANY LIMITED – Proposed placement of new ordinary shares - SENS
- 06/24/2020
|
UK Home Secretary under pressure to extend Indian doctors’ visas till end-2020
- These young medics came to the UK to complete their Professional Linguistic and Assessments Board (PLAB) assessment earlier this year and remain in limbo following the suspension of their exams and international flights.
- 06/24/2020
|
UK Home Secretary under pressure to extend Indian doctors’ visas till end-2020
- Britain’s leading doctors’ associations are calling on UK Home Secretary Priti Patel for an automatic fee-free extension of the short-term visas of many Indian doctors stranded in the lockdown as they await their international qualification exams in the UK.
- 06/24/2020
|
LEG Immobilien : NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH, OR TO PERSONS IN ANY JURISDICTION TO WHOM, SUCH DISTRIBUTION WOULD BE UNLAWFUL. | MarketScreener
|
Basilea launches the placement of CHF 100 million senior convertible bonds with an increase option of CHF 25 million | MarketScreener
|
Mapletree Industrial Trust : Close of Upsized Private Placement at an issue price of S$2.800 per New Unit | MarketScreener
|
Hyloris Pharmaceuticals Announces Narrowing of Price Range of its Initial Public Offering
|
Basilea launches the placement of CHF 100 million senior convertible bonds with an increase option of CHF 25 million
- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN Basel, Switzerland, June 24,...
- 06/24/2020
|
Amryt publicly files registration statement for impending US listing on Nasdaq
|
Telangana sees surge in Covid-19 cases as testing ramped up, private labs included
- =Since June 15, the state has witnessed 3,268 new cases, which is nearly 42 per cent of its overall cases to date. As of June 22, the total confirmed positive cases stands at 8674. Of them, 4,452 are active cases.
- 06/23/2020
|
CASTLEVIEW PROPERTY FUND LIMITED – Declaration of a cash dividend with the election to reinvest the cash dividend in return for Castleview shares - SENS
- Sens announcement for CASTLEVIEW PROPERTY FUND LIMITED – Declaration of a cash dividend with the election to reinvest the cash dividend in return for Castleview shares - SENS
- 06/23/2020
|
EANS-General Meeting: AMAG Austria Metall AG / Invitation to the
General Meeting according to art. 107 para. 3 Companies Act
|
Care Property Invest / : Emission de nouvelles actions via placement privé avec constitution accélérée d'un livre d'ordres auprès d'investisseurs institutionnels internationaux | Zone bourse
|
Amryt publicly files registration statement for impending US listing on Nasdaq
- THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION THIS ANNOUNCEMENT CONTAINS INSIDE...
- 06/23/2020
|
Hikma Pharmaceuticals : Proposed Placing in Hikma Pharmaceuticals PLC | MarketScreener
|
European Commission opens investigation into acquisition of Refinitiv by London Stock Exchange - FinanceFeeds
- The Commission is concerned that the proposed acquisition may reduce competition in trading and clearing of various financial instruments and in financial data products.
- 06/22/2020
|
SES Successfully Prices EUR 400 Million 8-Year Euro Bond
- LUXEMBOURG — SES S.A. announced today the successful launch and pricing of a bond offering in which it has agreed to sell senior unsecured fixed rate notes due in 2028 for a total amount of E…
- 06/22/2020
|
Esperion and Daiichi Sankyo Europe Announce Amendment to License and Commercial Collaboration Agreement | MarketScreener
|
EANS-Adhoc: ams AG / ams announces the offering of EUR 1,000 million
equivalent senior notes
- Financing 22.06.2020
- 06/22/2020
|
QIAGEN Announces Plans to Release Preliminary Q2 2020 Results
- QIAGEN announces plans to release preliminary Q2 2020 results
- 06/22/2020
|
The Province of Buenos Aires : Extends Expiration of Invitation Memorandum (as defined below)
|
The Republic of Argentina : Extends Expiration of its Prospectus Supplement (as defined below)
|
Binance Supports Purchase Of Crypto Via Visa In More Than 180 Countries
- As the cryptocurrency exchange, Binance is going turn 3 years old, the platform released a series of developments throughout the day. The exchange allowed the purchase of crypto through Visa for more than 180 countries. This was further followed by a few other developments. Binance Takes A Leap Towards Global Expansion Malta-based cryptocurrency exchange, Binance
- 06/19/2020
|
AU and Africa day: Is a new Africa possible? - TheCable
- BY CHUKWUEMEKA UWANAKA Another Africa Day was marked on May 25, 2020. The day represents the anniversary of the founding of the Organisation for African Union (OAU) in 1963, the
- 06/19/2020
|
EANS-General Meeting: Semperit AG Holding / Invitation to the
General Meeting according to art. 107 para. 3 Companies Act
|
How to get two free tickets to Legoland Windsor Resort
- GET ready to bank your codes! Sun Savers is back with another great family day out, you could snag two free tickets to LEGOLAND Windsor Resort this summer worth up to £110. Fancy a day out with Sun…
- 06/19/2020
|
Thorpe Park Resort: How to get two free tickets worth over £100 from Sun Superdays
- GET your code collecting fingers ready! Sun readers could snag two FREE tickets to Thorpe Park Resort this summer worth over £110. Plus, readers who collect with Sun Savers will get early access to…
- 06/19/2020
|
Brokerages Expect Alimera Sciences Inc (NASDAQ:ALIM) to Post -$1.62 Earnings Per Share
- Brokerages forecast that Alimera Sciences Inc (NASDAQ:ALIM) will announce earnings of ($1.62) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Alimera Sciences’ earnings. The highest EPS estimate is ($1.10) and the lowest is ($2.14). Alimera Sciences reported earnings per share of ($1.05) during the same quarter […]
- 06/19/2020
|
Up to half of rough sleepers in hotels may not have access to support when they leave, charities warn
- Campaigners say thousands of homeless people with no recourse to public funds may end up back on the streets because of lack of clarity from ministers
- 06/18/2020
|
Britain grants more than 3.3M EU, EEA citizens right to remain in U.K.
- Britain's Home Office said Thursday more than 3.3 million European Union and European Economic Area citizens have been granted the right to stay in the country permanently after Brexit.
- 06/18/2020
|
EANS-Adhoc: Atrium European Real Estate Limited / ATRIUM
SUCCESSFULLY ISSUES €200 MILLION UNSECURED EUROBONDS BY TAPPING ITS
€300 MILLION 3.000% EUROBONDS DUE 2025
- Capital Measures 18.06.2020
- 06/18/2020
|
More than 3.3m EU and EEA citizens granted right to remain in UK
- Home Office figures suggest high take-up rate despite anxieties surrounding Brexit
- 06/18/2020
|
Upjohn Announces Pricing of Senior Notes in Connection with the Proposed Combination of Mylan and Upjohn
- Upjohn Inc. (“Newco”), a wholly-owned subsidiary of Pfizer Inc. (“Pfizer”) (NYSE: PFE), Upjohn Finance B.V. (“Finco”), a wholly-owned subsidiary of Ne
- 06/18/2020
|
EU bank credit models neglect peripheral countries - Risk.net
- A majority of non-core EU exposures are under the standardised approach
- 06/17/2020
|
Care Property Invest : Agreement on the acquisition of a residential care centre with assisted living apartments in Lier (BE) | MarketScreener
|
Infineon Technologies : places €2.9 billion in bonds with maturities up to twelve years and thereby takes a significant further step to refinance the Cypress acquisition | MarketScreener
|
Fiat Chrysler Automobiles N : and Peugeot Merger Subject to EU Investigation | MarketScreener
|
UK has 240,000 doses of new breakthrough coronavirus drug in stock or on order
- Health Secretary Matt Hancock said the new drug, dexamethasone, is an "important moment" in the fight against the virus
- 06/17/2020
|
UK government has stockpiled 200,000 courses of life-saving drug dexamethasone
- The UK Government has stockpiled 200,000 courses of a steroid that is the first drug shown to save the lives of some people with COVID-19
- 06/17/2020
|
'We're not interested' Iceland's brutal rejection of EU membership revealed
- THE EUROPEAN UNION has sought to expand its influence in Europe by accepting more countries into the bloc - but Iceland brutally rejected Brussels with one figure claiming its interests wouldn't be served.
- 06/17/2020
|
Constellium Prices Notes Offering
- Constellium SE (NYSE: CSTM) (“Constellium” or the “Company”) today announced that the Company has priced a private offering (the “Notes Offering”) of $325
- 06/16/2020
|
New Strong Buy Stocks for June 16th
- New Strong Buy Stocks for June 16th
- 06/16/2020
|
Coronavirus: Government has been stockpiling life-saving steroid drug - Evening Telegraph
- The Government has stockpiled 200,000 courses of a steroid that is the first drug shown to save the lives of some people with coronavirus.
- 06/16/2020
|
Constellium Launches Proposed Senior Notes Offering
- Constellium SE (NYSE: CSTM) (“Constellium”) announced today the commencement of a proposed private offering of approximately $300 million of U.S. dollar
- 06/16/2020
|
European Commission opens two Apple antitrust investigations
- The European Commission has opened two antitrust investigations focusing on Apple Pay and the iOS App Store.
- 06/16/2020
|
Apple faces European antitrust investigations into App Store and Apple Pay
- The European Commission has opened an antitrust investigation into Apple's rules that force developers to use the company's in-app payment technology.
- 06/16/2020
|
State pension warning as triple lock under threat - these pensioners do not get increase
- STATE PENSION payments in the UK rise each year currently under the triple lock. A warning that the mechanism could be at risk of being axed has been issued, however some people already do not get to enjoy the increase.
- 06/15/2020
|
Latvia to limit Russian channels
- The Latvian parliament (Saeima) has approved at the third reading amendments to the Electronic Mass Media Law.
- 06/15/2020
|
MPs criticise exclusion of NHS workers from free visa extensions
- It will cost low-paid NHS and social care staff thousands to stay in UK, says report
- 06/14/2020
|
British holidaymakers face being banned from visiting US for MONTHS
- The current travel ban for UK tourists which has been in place since March 16 will likely be lifted in months rather than weeks, senior US virus expert Dr. Anthony Fauci said.
- 06/14/2020
|
France, Croatia and Greece to welcome British tourists from Monday
- People crowded to a beach in Barcelona (pictured) to sunbathe, play and swim in the first weekend that everyone is allowed to go to the beach.
- 06/13/2020
|
We now have a unique opportunity to end rough sleeping in London for good - CityAM
- Where do we go from here? It’s a question many of us are asking ourselves, as lockdown measures are gradually
- 06/13/2020
|
Sadiq Khan calls for government to support homeless Europeans - CityAM
- Sadiq Khan has today issued a call to provide support for homeless non-UK nationals, as temporary housing plans for rough sleepers come to a close.
- 06/13/2020
|
EU humiliated: Damning reason Norway rejected membership exposed
- THE EUROPEAN UNION has long wanted to expand its membership to bring more nations under its umbrella - but not all countries have taken to this idea.
- 06/13/2020
|
Mastercard Teams With Octet Europe For SMB Tech | PYMNTS.com
- Mastercard and Octet Europe rolled out a new trade system throughout the European Economic Area (EEA) to assist small- to medium-sized enterprises.
- 06/12/2020
|
Mastercard Teams Up With Octet Europe to Launch New Trade Solution Across European Economic Area
- Mastercard announced on Thursday it has joined forces with Octet Europe to launch of a new trade solution across the European Economic Area (EEA). According to
- 06/12/2020
|
State pension: Claimants aged 80 could get a boost of more than £80 a week – how to claim
- STATE Pension can come in two forms, basic and new state pension. The basic state pension was replaced by new state pension in 2016 and it is being phased out but there are some people who may still be receiving it.
- 06/12/2020
|
How GDPR will be impacted by Brexit
- Ambiguity during this transitional period
- 06/11/2020
|
Do Hedge Funds Love Alimera Sciences Inc (ALIM)?
- In this article we will take a look at whether hedge funds think Alimera Sciences Inc (NASDAQ:ALIM) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips […]
- 06/10/2020
|
Large caps deny they're being outgunned by smaller peers in health R&D - Stockhead
- The journey of each individual medical treatment from idea to market requires the involvement of multiple parties big and small. The general consensus seems to be that it takes a big player to get a drug to market, which more often than not means the smaller players enact some sort of M&A deal to get …
- 06/10/2020
|
Filled jobs fall 0.1 per cent: Aus shares close 0.1% higher
- 10 Jun 2020 - The Australian share market fell at the open, but closed 0.1 per cent up at the end of trade. Filled jobs fell by 0.1 per cent and hours worked by 0.8 per cent between the December and March quarters.
- 06/10/2020
|
Why the Opthea share price has skyrocketed 350% in the past year
- The Opthea Ltd (ASX: OPT) share price has been a standout performer in the mid-cap ASX healthcare sector, up more than 350% in the past 12 months.
- 06/10/2020
|
What's Opthea eyeing now that it has two successful trials under its belt? - Stockhead
- Having now proven its drug works on two eye diseases, Opthea (ASX:OPT) is looking to future treatment options. The immediate consideration for Opthea is a phase three study on Diabetic Macular Edema (DME), similar to its planned phase three study in wet-AMD. The company will spend the next few months planning the DME study but the wet-AMD …
- 06/10/2020
|
Opthea (ASX:OPT) reports positive trial results: Aus shares 0.5% higher at noon
- 10 Jun 2020 - The Australian share market opened lower but is now trading 0.5 per cent up at noon. Opthea (ASX:OPT) has reported positive Phase 2a trial results for its OPT-302 treatment in Diabetic Macular Edema.
- 06/10/2020
|
Opthea's done it again: Its drug passed its DME clinical trial - Stockhead
- Ten months since Opthea’s (ASX:OPT) drug proved itself against wet-AMD, it’s passed another clinical trial against Diabetic Macular Edema (DME). This morning the company conducted a 144-patient phase 2a clinical trial against DME, which is a smaller market than wet-AMD, but is similar in that it results in vision loss from fluid leakage in the …
- 06/10/2020
|
Daiichi Sankyo’s SANTORINI Study Gets Underway, Investigating Cholesterol Care Across Europe
- Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) today announced that the first patients have been enrolled in a multinational, prospective, o
- 06/10/2020
|
Zurich Insurance : announces the successful placement of EUR 750 million of dated subordinated debt | MarketScreener
|
Vetoquinol Is Moving Forward With the Acquisition of Profender® And Drontal® And Related Pipeline Assets Following Communication From the European Commission
- Regulatory News: The European Commission (EC) has approved, under the EU merger Regulation, the proposed acquisition of Bayer’s Animal Health Division
- 06/09/2020
|
EC approves Elanco's purchase of Bayer animal health business
- $7.6 billion deal announced in August 2019; expected to be completed by mid-year 2020.
- 06/08/2020
|
Commission grants approval for Elanco to acquire Bayer's animal health business
- The European Commission has granted approval to Elanco Animal Health's pending acquisition of Bayer's animal health business.
- 06/08/2020
|
IP lock-out: Is Britain handing the EU the keys to a billion-pound industry? - CityAM
- We are getting close to crunch point in the Brexit negotiations. Last week saw the culmination of the final round
- 06/08/2020
|
Have to deal with every patient as potential COVID case: Telangana DME
- As the number of fatalities due to COVID-19 in Telangana stands at 113 as of June 5, with the 100-figure mark having breached the previous day, it is interesting to note that 79 of these deaths were reported in the last 19 days.
- 06/06/2020
|
EANS-General Meeting: Andritz AG / Invitation to the General Meeting
according to art. 107 para. 3 Companies Act
|
Genetron Health Receives FDA Emergency Use Authorization for SARS-CoV-2 RNA Test and Approval for Export by Chinese Authority
- Genetron Holdings Limited (“Genetron Health”), a China-based precision oncology company that covers full-cycle cancer care, announced that its indepen
- 06/06/2020
|
BankBazaar Scores $6 Million; PayPal Makes Strategic Investment in Tink - Finovate
- Courtesy of a round featuring new investor WSV – a joint venture fund of Walden International and Korean firm SKTA – online financing solutions marketplace BankBazaar has raised $6 million in new equity funding. The company will use the capital, which adds to an existing Series D round, to help market its contactless personal finance Read more...
- 06/05/2020
|
EANS-General Meeting: AGRANA Beteiligungs-AG / Invitation to the
General Meeting according to art. 107 para. 3 Companies Act
|
Longevity Card Secures Investors, Eyes Q4 2020 Launch
- Longevity, a U.K.-based digital bank, formally announced it secured investors for a funding round that will help launch a new mobile banking experience, Longevity Card, by the...
- 06/04/2020
|
Credit Agricole : Crédit Agricole S.A. Announces Pricing of its Tender Offers for USD Senior Preferred Notes | MarketScreener
|
47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th
- NEW YORK, NY / ACCESSWIRE / June 3, 2020 / The Virtual Summer Summit will take place on June 9 th -12 th , connecting 47 presenting small and microcap companies with distinguished investors from around ...
- 06/03/2020
|
EANS-General Meeting: voestalpine AG / Invitation to the General
Meeting according to art. 107 para. 3 Companies Act
|
Alimera to Present at the June 2020 Virtual Summer Investor Summit
- Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announced that Rick Eiswirth, Alimera’s President and Chief Executive Officer will give a corporate presentation at the June 2020 Virtual Summer Investor Summit taking place online from June 9- 12, 2020. Alimera is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people globally.
- 06/03/2020
|
Tink Receives Strategic Investment from PayPal | FinSMEs
- Tink, a Stockholm, Sweden-based open banking platform that enables banks, fintechs and startups to develop data-driven financial services, received a strategic investment from PayPal (Nasdaq: PYPL)
- 06/03/2020
|
World's first plastic free PPE goes on sale
- The Plastic Free PPE REELshield is priced at 50p an item. It is made from responsibly-sourced paper, the headband, and cellulose extracted from woodpulp, the visor.
- 06/02/2020
|
Lithuania Opens Borders - Rus Tourism News
- Lithuania is opening its borders to citizens of countries where coronavirus cases have been below 25 per population of 100,000 for the past two weeks.
- 06/02/2020
|
EU humiliated: Bloc's bitter trading row with Switzerland revealed
- THE EUROPEAN UNION and Switzerland have had a chaotic past - and just when their relationship seemed at its strongest, a bitter trading row opened old wounds once again.
- 06/02/2020
|
Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares
- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today announced the pricing of an underwritten public
- 06/02/2020
|
Gelesis Receives Approval to Market PLENITY™ in Europe as a Weight Loss Treatment
- Gelesis, a biotechnology company developing a novel hydrogel platform technology to treat obesity and other chronic diseases related to the gastrointe
- 06/02/2020
|
State Pension UK: Boris Johnson makes new Triple Lock commitment but you may miss out
- STATE PENSION gets an annual boost through the Triple Lock scheme, which was first devised in 2011 by the then-coalition government. However, there is one group of people who are likely to miss out on the yearly rise.
- 05/31/2020
|
Signify N : successfully prices EUR 1.275 billion of Eurobonds to refinance the bridge loan arranged to finance Cooper Lighting acquisition | MarketScreener
|
Applying for UK citizenship: New guidance for EU nationals
- (Partner Content) New Home office guidance for UK nationality caseworkers details three important requirements for EEA nationals when claiming UK citizenship.
- 05/27/2020
|
PIP: Who qualifies for PIP? How to claim PIP
- PIP or Personal Independence Payment is a benefit which can help you if you have a long term health problem or disability. But who qualifies for PIP? Here is how to claim PIP.
- 05/27/2020
|
Full terms and conditions for weekly competition
- Sun Win competitions – General Terms & Conditions Promotion starts at 00.01 on 27/05/2020. SMS entry closes 07/06/202023:59 pm and postal entry closes 09/06/2020 at 23.59 pm. Open to resi…
- 05/27/2020
|
Have you been left short changed by government pension blunders?
- Campaigners are calling for the Department for Work and Pensions to conduct a full investigation into how many women have missed out on their pensions and how it was allowed to happen.
- 05/26/2020
|
Time to Transform Your DME Billing Process for A Better ROI
- One of your neighbors posted in Neighbor News. Click through to read what they have to say. (The views expressed in this post are the author’s own.)
- 05/26/2020
|
How IoT, AI And Big Data Can Enable Environmental Sustainability
- An uninhabitable planet — the inevitable future or a risk that humanity can still overcome? Cornell researcher states that approximately…
- 05/25/2020
|
Poxel Successfully Raises €17.7 Million in a Capital Increase
- POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders,
- 05/25/2020
|
Piers Morgan admits defeat and apologises as GMB guest erupts at host: 'You were right'
- PIERS MORGAN was corrected by one of his guests on Good Morning Britain on Thursday, leading to his defeat as he was forced to apologise to journalist Andrew Pierce for misinterpreting a comment he made about the NHS surcharge.
- 05/23/2020
|
You'll need an EU pet passport to travel with your dog to Britain from next year
- That means an addition £60 per animal and each one will need rabies jabs
- 05/23/2020
|
Boris told to 'walk away' from EU Brexit talks and leave on WTO terms NOW - 'No question!'
- EXPRESS.CO.UK readers have urged Boris Johnson to walk away from Brexit trade talks with the European Union and secure a future relationship with the bloc on World Trade Organisation (WTO) rules.
- 05/22/2020
|
Brexit boost: How Switzerland claimed 'UK will get better deal than us'
- BREXIT trade talks have reached a stage of stalemate as the EU and UK stand firmly by their demands - but another country with a long history of Brussels feuds could give Boris Johnson cause for optimism.
- 05/22/2020
|
Charging migrant NHS workers a fee for using the service was always callous
- Now, there's been an outbreak of common sense in the Commons, writes i's editor
- 05/21/2020
|
Coronavirus: Johnson in U-turn on NHS use fee for migrant health staff
- British PM pressured by Starmer to exempt key workers in Covid fight from £400 charge
- 05/21/2020
|
Johnson forced to drop NHS surcharge for migrant health workers
- Downing Street bows to pressure from opposition and backbench Tories amid crisis
- 05/21/2020
|
Johnson U-turns on ‘immoral’ NHS charge for migrant health workers after pressure from MPs
|
Foxes legend Gary Lineker's brilliant response to Twitter trolls
- The Match of the Day presenter posted about fees some overseas health workers are being charged to use the NHS
- 05/21/2020
|
Piers Morgan says 'disgusting' Boris Johnson is 'slapping NHS workers in face'
- Migrant workers are charged £400 a year to use the NHS, including those who work for it, even though their income tax already funds the NHS
- 05/21/2020
|
Placenta Growth Factor Pipeline Review, H1 2020: Companies Involved in Therapeutics Development - ResearchAndMarkets.com
|
'We feel insulted': migrant health workers on PM's refusal to scrap NHS surcharge
- Fee for care and health workers from outside the European Economic Area to rise to £624 a year in October
- 05/20/2020
|
